7-乙酰基-2-吲哚羧酸 | 133738-76-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 中文名称: 7-乙酰基-2-吲哚羧酸
• 英文名称: 7-acetyl-1H-indole-2-carboxylic acid
• 英文别名: 7-acetylindole-2-carboxylic acid
• CAS: 133738-76-8
• 化学式: C₁₁H₉NO₃
• 分子量: 203.197
• InChiKey: HKCBXLRQUQSXEB-UHFFFAOYSA-N

物化性质

• 沸点：
  478.9±25.0 °C(Predicted)
• 密度：
  1.392±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  70.2
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  N-(1-甲基乙基)-2-(1-哌嗪)-3-氨基吡啶双盐酸盐水合物 、 7-乙酰基-2-吲哚羧酸 在 carbonyl 1,1'-diimidazole 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 18.0h， 以58%的产率得到1-(2-(4-(3-(isopropylamino)pyridin-2-yl)piperazine-1-carbonyl)-1H-indol-7-yl)ethanone
  参考文献：
  名称：

  Design and synthesis of dual inhibitors of HIV reverse transcriptase and integrase: Introducing a diketoacid functionality into delavirdine

  摘要：

  Cost and toxicity problems associated with highly active antiretroviral therapy (HAART) in HIV/AIDS treatment could be alleviated by using designed multiple ligands (DMLs). Dual inhibitors of HIV reverse transcriptase (RT) and integrase (IN) were rationally designed by introducing a diketoacid (DKA) functionality into the tolerant C-5 site of RT inhibitor delavirdine. The resulting compounds all demonstrate good activity against both RT and IN in enzymatic assays and HIV in cell-based assay, whereas their C-7 regioisomers are all inactive in these assays. Balanced activities were observed with C-3 halogenated inhibitors. (C) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2008.02.007
• 作为产物：
  描述：

  ethyl 7-acetyl-1H-indole-2-carboxylate 在 sodium hydroxide 作用下， 以 乙醇 、 二氯甲烷 为溶剂， 反应 5.0h， 以37%的产率得到7-乙酰基-2-吲哚羧酸
  参考文献：
  名称：

  Design and synthesis of dual inhibitors of HIV reverse transcriptase and integrase: Introducing a diketoacid functionality into delavirdine

  摘要：

  Cost and toxicity problems associated with highly active antiretroviral therapy (HAART) in HIV/AIDS treatment could be alleviated by using designed multiple ligands (DMLs). Dual inhibitors of HIV reverse transcriptase (RT) and integrase (IN) were rationally designed by introducing a diketoacid (DKA) functionality into the tolerant C-5 site of RT inhibitor delavirdine. The resulting compounds all demonstrate good activity against both RT and IN in enzymatic assays and HIV in cell-based assay, whereas their C-7 regioisomers are all inactive in these assays. Balanced activities were observed with C-3 halogenated inhibitors. (C) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2008.02.007

文献信息

• CBI analogues of the duocarmycins and CC-1065
  申请人：Boger L. Dale

  公开号：US20050026987A1

  公开（公告）日：2005-02-03

  An extensive series of CBI analogues of the duocarmycins and CC-1065 exploring substituent effects within the first indole DNA binding subunit is detailed. In general, substitution at the indole C5 position led to cytotoxic potency enhancements that can be ≧1000-fold providing simplified analogues containing a single DNA binding subunit that are more potent (IC 50 =2-3 pM) than CBI-TMI, duocarmycin SA, or CC-1065. The increases in cytotoxicity correlate well with accompanying increases in the rate and efficiency of DNA alkylation. This effect is more pronounced with the CBI versus DSA or CPI based analogues. Moreover, this effect is largely insensitive to the electronic character of the C5 substituent but is sensitive to the size, rigid length, and shape (sp, sp 2 , sp 3 hybridization) of this substituent consistent with expectation that the impact is due simply to its presence.

  一系列广泛的CBI类似物，包括二聚卡蜜素和CC-1065的类似物，探索了第一个吲哚DNA结合亚基中取代基效应的细节。一般来说，在吲哚C5位置的取代导致细胞毒性增强，可以达到≧1000倍，提供了更强效（IC50=2-3 pM）的含有单个DNA结合亚基的简化类似物，比CBI-TMI、二聚卡蜜素SA或CC-1065更有效。细胞毒性增加与DNA烷基化速率和效率的增加密切相关。与基于DSA或CPI的类似物相比，这种效应在CBI类似物中更为显著。此外，这种效应对于C5取代基的电子性质不太敏感，但对于取代基的大小、刚性长度和形状（sp、sp2、sp3杂化）敏感，这与预期一致，即这种影响仅仅是由于其存在。
• Indole nitriles
  申请人：——

  公开号：US20040077646A1

  公开（公告）日：2004-04-22

  Compounds of the formula (I) 1 wherein m, n, R 1 , R 2 , R 3 , R 4 , R 5 and R 6 are as described herein, together with methods for making the compounds and using the compounds for treatment of diseases or conditions mediated by Cathepsin K.

  式(I)的化合物，其中m、n、R1、R2、R3、R4、R5和R6如本文所述，以及制备这些化合物的方法和利用这些化合物治疗由Cathepsin K介导的疾病或症状的方法。
• KINASE INHIBITORS, COMPOSITIONS THEREOF, AND METHODS OF USE THEREWITH
  申请人：Shoemaker Robert

  公开号：US20090018141A1

  公开（公告）日：2009-01-15

  Provided herein are Compounds having the following structure: wherein A, L, X and ring B are as defined herein, compositions comprising an effective amount of a Compound and methods for treating or preventing cancer, hypoxia, diabetes, stroke, autoimmune disease or a condition treatable or preventable by inhibition of Chk2, the ATM-Chk2 pathway or RSK2 comprising administering an effective amount of a Compound to a patient in need thereof.

  本文提供具有以下结构的化合物：其中A、L、X和环B如本文所定义，包括有效量的化合物的组合物以及用于治疗或预防癌症、缺氧、糖尿病、中风、自身免疫疾病或通过抑制Chk2、ATM-Chk2途径或RSK2治疗或预防的情况的方法，包括向需要该化合物的患者施用有效量的化合物。
• Establishment of substituent effects in the DNA binding subunit of CBI analogues of the duocarmycins and CC-1065
  作者：Jay P. Parrish、David B. Kastrinsky、Frederic Stauffer、Michael P. Hedrick、Inkyu Hwang、Dale L. Boger

  DOI：10.1016/s0968-0896(03)00194-9

  日期：2003.8

  An extensive series of CBI analogues of the duocarmycins and CC-1065 exploring substituent effects within the first indole DNA binding subunit is detailed. In general, substitution at the indole C5 position led to cytotoxic potency enhancements that can be greater than or equal to 1000- fold providing simplified analogues containing a single DNA binding subunit that are more potent (IC50 = 2-3 pM) than CBI-TMI, duocarmycin SA, or CC-1065. (C) 2003 Elsevier Ltd. All rights reserved.
• US8765802B2
  申请人：——

  公开号：US8765802B2

  公开（公告）日：2014-07-01